| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
LENSAR, Inc.$6.01
+0.08 (+1.35%)
F 2Pipeline Score MedTech · Commercial
Market Cap
73.72 M
EPS
0.98
P/E Ratio
-
Value Trade
304.44 K
SEC Financials
Q1 2026Dilution Risk
Revenue
13.43 M
R&D Expenses
1.39 M
Operating CF
-4.27 M
Total Assets
66.22 M
Total Liabilities
41.65 M
Equity
10.79 M
D/E Ratio
12,345
6.1 %
Week
12.78 %
1 Month
-46.25 %
3 Month
-37.15 %
6 Month
-23.01 %
5 Year
92.72 %
All Time
Cash Data
Cash Position
13.49 M
Monthly Burn
1.42 M
Runway
7.4 mo
Burn Trend
SEC Filing
May 8, 2026
Overview
Volume
14.15 K
52 Week Range
5.06 - 13.74
% held by Insiders
20.19 %
% held by Institutions
52 %
Enterprise Value
76.58 M
Total Shares
11.94 M
Short %
6.6 %
Float Shares
7.66 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F2
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 4%
Micro Cap (rank 877 of 912)
Percentile RankLENSAR, Inc. has significant pipeline risk (2/100), but cash runway is a concern.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LNSR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LNSR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LNSR▲ +7.8%on this news
LENSAR® Reports First Quarter 2026 Results and Provides Business Update
LENSAR, Inc. reported its first quarter 2026 results, revealing a total revenue of $13.4 million, a 5% decrease from the previous year. Despite this, the company saw a 39% growth in ALLY System placements and a 12% increase in its total installed base. Management remains optimistic about future growth in recurring revenue as market uncertainties lessen.
Read more →LNSRLENSAR® to Report First Quarter 2026 Results on May 8, 2026
LENSAR, Inc. will release its first quarter 2026 financial results on May 8, 2026. The company will host a conference call and webcast at 8:30 am ET to discuss these results and provide updates on corporate initiatives. The ALLY Robotic Cataract Laser System™ is a key product aimed at enhancing cataract surgery.
Read more →LNSRLENSAR® Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
LENSAR, Inc. reported its financial results for Q4 and full year 2025, highlighting a 48% growth in its ALLY installed base and a 15% increase in recurring revenue. Despite a slight decline in total revenue for Q4, the company experienced a significant rise in worldwide procedure volume. The management emphasized a commitment to advancing robotic laser cataract surgery following the termination of a merger agreement with Alcon.
Read more →LNSR▼ -32.8%on this news
LENSAR Announces Termination of Merger Agreement with Alcon Research, LLC Company to Report Fourth Quarter Financial Results and Provide Strategic Update on
LENSAR, Inc. has announced the termination of its merger agreement with Alcon Research, LLC, citing regulatory challenges from the Federal Trade Commission. The companies mutually agreed that proceeding with the merger was not in their best interests due to regulatory approval uncertainties. Despite this setback, LENSAR remains focused on its ALLY Robotic Cataract Laser System and plans to report its fourth quarter financial results on March 31, 2026. The company aims to advance its technology and market share in the cataract surgery field, although the termination may impact its business operations and relationships.
Read more →LNSRLENSAR® Provides Update on Pending Acquisition by Alcon
LENSAR, Inc. has provided an update on its pending acquisition by Alcon Research, LLC, indicating cooperation with the FTC for regulatory review. The company anticipates closing the transaction in the first half of 2026, contingent upon satisfying closing conditions. However, there are risks associated with regulatory approvals and potential delays.
Read more →LNSR▼ -8.6%on this news
LENSAR® Reports Third Quarter 2025 Results and Provides Business Update
LENSAR, Inc. reported a 6% increase in revenue for Q3 2025, totaling $14.3 million, driven by an 11% rise in procedure volume. The company placed 18 ALLY Systems, boosting its installed base by 77% year-over-year. However, net losses increased to $3.7 million, largely due to costs associated with the pending acquisition by Alcon. The company anticipates closing the merger in Q1 2026.
Read more →LNSRLENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LENSAR, Inc. announced the grant of 660 restricted stock units (RSUs) to three newly-hired non-executive employees as an inducement for their employment. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and is part of LENSAR's strategy to attract talent. The RSUs will vest over four years, contingent on continued service.
Read more →LNSRLENSAR Reports Second Quarter 2025 Results and Provides Business Update 18 ALLY Robotic Cataract Laser Systems (“ALLY Systems”) placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending instal
LENSAR, Inc. reported its second quarter 2025 financial results, highlighting a 107% growth in the installed base of its ALLY robotic cataract laser systems and a 23% increase in worldwide procedure volumes compared to the same period in 2024. The proposed merger with Alcon has progressed, with over 99% of stockholder votes in favor, and the company expects closure by year-end. Despite a revenue increase of 10% to $13.9 million, the company posted a net loss of $1.8 million due to rising operational costs.
Read more →LNSRLENSAR Reports First Quarter 2025 Results and Provides Business Update 14 ALLY Robotic Laser Cataract Systems (“ALLY Systems”) placed in 1Q 2025 with an additional backlog of 24 systems pending installation
LENSAR, Inc. reported solid financial results for the first quarter of 2025, with significant increases in revenue and procedure volumes compared to the previous year. The company placed 14 ALLY Robotic Laser Cataract Systems, reflecting a growing operational base. However, LENSAR also noted an increase in net losses driven by changes in warrant liability and higher expenses tied to the proposed merger with Alcon Research. The company aims to enhance its market position through this strategic acquisition.
Read more →LNSRAlcon Agrees to Acquire LENSAR, Inc.
Alcon has announced its intention to acquire LENSAR for $14.00 per share, totaling approximately $356 million, with potential additional payments based on performance milestones. This acquisition aims to integrate LENSAR's advanced laser technologies into Alcon's offerings, enhancing its capabilities in cataract surgery. The deal is expected to close in mid-to-late 2025, pending regulatory and stockholder approvals.
Read more →LNSRCOMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG Alcon Agrees to Acquire LENSAR, Inc. Acquisition of ALLY Robotic Cataract Laser Systems strengthens Alcon s cataract equipment and technology portfolio Next generation
Alcon has announced its intention to acquire LENSAR, Inc., enhancing its portfolio in the cataract treatment market. The deal involves purchasing outstanding shares at $14 each, with potential additional funds linked to procedure milestones. This acquisition will incorporate LENSAR's ALLY Robotic Cataract Laser Treatment System and advanced software technology, aimed at improving the efficiency of cataract surgeries. However, the merger is subject to customary conditions, including regulatory approvals, which could pose challenges. Overall, this move is expected to solidify Alcon's leadership in eye care technology.
Read more →LNSR▲ +14.8%on this news· ran to +48% by day 3shared move
LENSAR Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update 31 ALLY Robotic Cataract Laser Systems placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023;
LENSAR, Inc. announced its financial results for Q4 and FY 2024, highlighting a strong performance with a total revenue increase of 27% over 2023. The company placed 31 ALLY systems in Q4, contributing to an annual total of over 80 placements and a notable 23% rise in recurring revenue. However, LENSAR faced challenges, reporting a significant net loss of $31.4 million for the year predominantly due to changes in warrant liability and an impairment charge. Despite the losses, LENSAR achieved over 20% market share in the U.S. procedure market for the first time in its history.
Read more →LNSRLENSAR to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 27, 2025
LENSAR, Inc. will release its fourth quarter and full year 2024 financial results on February 27, 2025. A conference call and webcast will follow at 8:30 am ET to discuss these results and recent corporate highlights. The company specializes in advanced robotic laser solutions for cataract treatment, enhancing operational efficiencies in surgical settings.
Read more →LNSRLENSAR to Participate in the BTIG 4th Annual Ophthalmology Day
LENSAR, Inc. will participate in the BTIG 4th Annual Ophthalmology Day on December 2, 2024. CEO Nick Curtis will engage in a fireside chat during the event, which is exclusive to BTIG clients. LENSAR is recognized for its advanced robotic laser solutions for cataract treatment, particularly with its ALLY Robotic Cataract Laser System that leverages AI and advanced imaging technologies for enhanced surgical efficiency.
Read more →LNSR▲ +17.2%on this news
LENSAR Reports Third Quarter 2024 Results and Provides Business Update 24 ALLY Robotic Laser Cataract Systems placed in 3Q 2024 including 11 sales in EU and Southeast Asia; Robust backlog with 24 systems pending installa
LENSAR, Inc. reported strong third quarter financial results for 2024, highlighting a 38% increase in total revenue compared to the same period in 2023. The company placed 24 ALLY Robotic Laser Cataract Systems, with significant sales in the EU and Southeast Asia. Additionally, procedure volumes rose by 29%, paralleling a 20% growth in the installed system base. Despite these gains, LENSAR faced a net loss of $1.5 million, as expenses grew due to various operational costs.
Read more →LNSRLENSAR to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
LENSAR, Inc. has announced the release date for its third quarter 2024 financial results, which will be available before market opening on November 7, 2024. In conjunction with this release, the company will host a conference call and webcast to discuss its financial performance and recent company highlights. LENSAR is recognized for its advanced robotic laser solutions aimed at improving cataract treatment, underscoring its position in the medical technology field.
Read more →LNSR▼ -9.9%on this news
LENSAR Reports Second Quarter 2024 Results and Provides Business Update 17 New ALLY Adaptive Cataract Treatment Systems placed in 2Q 2024; highest number of placements since launch Received Medical Device Regulation (MDR
LENSAR, Inc. reported its second quarter 2024 results, highlighting solid growth with 17 new placements of its ALLY Adaptive Cataract Treatment Systems, the highest since launch. The company also received regulatory approvals in Europe and Taiwan, enhancing its market access. Despite these successes, LENSAR reported a net loss of $9 million and recorded an impairment charge on intangible assets. The overall procedure volume increased by 19% compared to the previous year, indicating robust market demand despite financial challenges.
Read more →LNSR▲ +12.7%on this news
LENSAR Reports First Quarter 2024 Results and Provides Business Update Total Revenue increased 28% and Procedure volume increased 25% over the first quarter of 2023 Increased ALLY Adaptive Cataract Treatment System insta
LENSAR, Inc. reported strong financial results for the first quarter of 2024, with total revenue increasing by 28% to $10.6 million compared to the same period in 2023. The company experienced a notable 25% growth in procedure volume, alongside an increase in its installed base of all systems to 65. Despite these positive indicators, LENSAR reported a net loss of $2.2 million, though this was an improvement relative to the previous year. Management anticipates continued growth in the U.S. market and internationally, pending regulatory approvals.
Read more →LNSRLENSAR Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update 44 ALLY Adaptive Cataract Treatment Systems were placed in 2023, significantly exceeding the target of 30, increasing the ALLY install
LENSAR, Inc. reported its financial results for Q4 and the full year of 2023, showcasing significant growth in revenue driven by the placement of ALLY Adaptive Cataract Treatment Systems. The company exceeded its target with a total of 44 installations in 2023. Despite the positive financial uptick, LENSAR faced a net loss of $3.9 million in Q4, which is notable compared to a smaller loss the previous year. Additionally, the company continues to address challenges in procedure volume, particularly in South Korea due to reimbursement complications.
Read more →LNSR▲ +12.4%on this news
LENSAR Reports Third Quarter 2023 Results and Provides Business Update Increased ALLY Adaptive Cataract Treatment System installed base to 39 systems with a backlog of 8 additional systems for installation as of
LENSAR, Inc. reported a strong performance in Q3 2023, with total revenue of $9.8 million, up 26% year-over-year. The U.S. procedure volume saw a 16% increase as well, aided by the installation of additional ALLY Adaptive Cataract Treatment Systems. Despite success in the U.S., the company noted decreased procedure volume in South Korea due to ongoing reimbursement challenges. Looking ahead, LENSAR aims to continue its growth and expand internationally in 2024.
Read more →LNSR▲ +12.7%on this news
LENSAR Reports Second Quarter 2023 Results and Provides Business Update Increased ALLY Adaptive Cataract Treatment System installed base to 28 systems with a backlog of 6 additional systems for installation as of
LENSAR reported strong financial results for the second quarter of 2023, with revenue increasing nearly 50% year-over-year to $12.0 million. The company also saw a 13% uplift in U.S. procedure volumes compared to the same quarter last year. The installed base of the ALLY Adaptive Cataract Treatment System reached 28 systems, with an additional backlog of 6 systems pending installation. However, the company reported a higher net loss compared to the previous year, impacted by third-party reimbursement challenges in South Korea.
Read more →LNSRLENSAR Reports First Quarter 2023 Results and Provides Business Update Increased ALLY Adaptive Cataract Treatment System installed base to 19 systems with a backlog of additional 13 systems as of
LENSAR, Inc. reported its Q1 2023 results, highlighting a growing base of the ALLY Adaptive Cataract Treatment Systems with 19 installations and a backlog of 13 additional systems. Despite a 12% revenue drop largely attributable to the loss of procedures in South Korea, total procedure volumes in the U.S. increased by 13%. The company also raised $20 million through a private placement, which is expected to bolster their market presence and support continued development of the ALLY system.
Read more →LNSRLENSAR Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update Installed ten ALLY Adaptive Cataract Treatment Systems in 2022 with contracts for six additional ALLY Systems executed in December 202
LENSAR, Inc. reported its financial results for Q4 and the full year 2022, highlighting the installation of ten ALLY Adaptive Cataract Treatment Systems and contracts for six more. While the surgeon feedback on ALLY has been overwhelmingly positive, indicating operational efficiencies and improved patient outcomes, the company also faced challenges including a decline in quarterly revenue and rising administrative expenses. Despite these setbacks, LENSAR aims for over 20% revenue growth as it enters a full launch year for the ALLY system.
Read more →LNSRLENSAR Announces Preliminary Fourth Quarter and Full Year 2022 Results Installed ten ALLY Adaptive Cataract Treatment Systems in 2022 Contracts for an additional six ALLY Systems executed in December 2022; Installations
LENSAR, Inc. has announced its preliminary financial results for the fourth quarter and full year of 2022, showcasing the successful installation of ten ALLY Adaptive Cataract Treatment Systems and contracts for six additional systems expected to be installed in 2023. Despite achieving revenue growth from the previous quarter, the company experienced a decline in revenue compared to the same quarter in the prior year due to reduced procedure revenue in South Korea. The company is optimistic about addressing supply chain challenges and expanding the availability of its technology in the coming year.
Read more →LNSR▼ -11.6%on this news
LENSAR Reports Third Quarter 2022 Financial Results and Provides Business Update Company Launches ALLY Adaptive Cataract Treatment System Third Quarter U.S. Procedure Volume Increases 9% over Q3 2021 ORLANDO, Fla. (
LENSAR Reports Third Quarter 2022 Financial Results and Provides Business Update Company Launches ALLY Adaptive Cataract Treatment System Third Quarter U.S. Procedure Volume Increases 9% over Q3 2021 ORLANDO, Fla. (November 9, 2022) LENSAR, Inc. (Nasdaq: LNSR) ( LENSAR or the
Read more →LNSRLENSAR Announces Application for Certification of the ALLY Adaptive Cataract Treatment System in the EU ORLANDO, Fla. (
LENSAR Announces Application for Certification of the ALLY Adaptive Cataract Treatment System in the EU ORLANDO, Fla. (September 8, 2022) LENSAR, Inc. (Nasdaq: LNSR) ( LENSAR or the Company ), a global medical technology company focused on advanced femtosecond laser surgical so
Read more →LNSRFirst Patients Treated with LENSAR's ALLY Adaptive Cataract Treatment System
First Patients Treated with LENSAR's ALLY Adaptive Cataract Treatment System August 16, 2022 ORLANDO, Fla.--(BUSINESS WIRE)-- LENSAR, Inc. (NASDAQ: LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for
Read more →LNSRLENSAR Reports Second Quarter 2022 Financial Results and Provides Business Update Company Receives FDA Clearance of ALLY Adaptive Cataract Treatment System Second Quarter Procedure Volume Increases 8%, in the Aggregate,
LENSAR Reports Second Quarter 2022 Financial Results and Provides Business Update Company Receives FDA Clearance of ALLY Adaptive Cataract Treatment System Second Quarter Procedure Volume Increases 8%, in the Aggregate, and 15% in the U.S. Over Q2 2021 Levels ORLANDO, Fla. (Au
Read more →LNSRLENSAR’s Ally Laser Cataract System cleared by FDA: Parkhurst NuVision will be among the first in US to offer
San Antonio, June 14, 2022 (GLOBE NEWSWIRE) -- The Ally Lensar laser is a cataract treatment system that combines a femtosecond laser for cataract surgery with phacoemulsification in a single medical device. Phacoemulsification, which uses ultrasound technology, has been the gol
Read more →LNSRLENSAR Receives U.S. FDA Clearance of ALLY Adaptive Cataract Treatment System
LENSAR Receives U.S. FDA Clearance of ALLY Adaptive Cataract Treatment System June 13, 2022, ORLANDO, Fla. LENSAR, Inc. (NASDAQ: LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of c
Read more →LNSRLENSAR Reports First Quarter 2022 Financial Results and Provides Business Update First Quarter Revenue Increases 33% Over 2021 Levels First Quarter Procedure Volume Increases 38% Over 2021 Levels ORLANDO, Fla. (
LENSAR Reports First Quarter 2022 Financial Results and Provides Business Update First Quarter Revenue Increases 33% Over 2021 Levels First Quarter Procedure Volume Increases 38% Over 2021 Levels ORLANDO, Fla. (May 9, 2022) - LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Compa
Read more →LNSR▲ +6.3%on this news
LENSAR Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update 2021 Revenue Increases $8.1 million or 31% over 2020 Levels Procedure Volume Increases over 2020 Levels by 37% in Fourth Qua
LENSAR Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update 2021 Revenue Increases $8.1 million or 31% over 2020 Levels Procedure Volume Increases over 2020 Levels by 37% in Fourth Quarter and by 35% in 2021 Cash and Cash Equivalents of $31.
Read more →LNSRLENSAR Reports Third Quarter 2021 Financial Results and Provides Business Update Third Quarter 2021 Procedure Volumes Increase 23% over 2020 Levels Cash and Cash Equivalents of $32.3 Million reflect Cash Utilization of $
LENSAR Reports Third Quarter 2021 Financial Results and Provides Business Update Third Quarter 2021 Procedure Volumes Increase 23% over 2020 Levels Cash and Cash Equivalents of $32.3 Million reflect Cash Utilization of $2.2 Million in the Quarter ORLANDO, Fla. (November 8, 202
Read more →LNSRLENSAR, Inc. STATEMENTS OF OPERATIONS (In thousands, except per share amounts) Three Months Ended June 30, Six Months Ended
LENSAR Reports Second Quarter 2021 Financial Results and Provides Business Update Second Quarter and First Half 2021 Procedure Volumes Increase 70% and 42% over 2020 Levels Cash and Cash Equivalents of $34.6 Million reflects Cash Utilization of $1.3 Million in the Second Quarte
Read more →LNSRLENSAR Reports First Quarter 2021 Financial Results and Provides Business Update First Quarter 2021 Procedure Volumes Increase 21.1% over First Quarter 2020 Cash and Cash Equivalents of $35.9 Million as of
LENSAR Reports First Quarter 2021 Financial Results and Provides Business Update First Quarter 2021 Procedure Volumes Increase 21.1% over First Quarter 2020 Cash and Cash Equivalents of $35.9 Million as of March 31, 2021 ORLANDO, Fla. (May 5, 2021) - LENSAR, Inc. (Nasdaq: LNSR
Read more →LNSRLENSAR Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Fourth Quarter 2020 Procedure Volumes Consistent with Fourth Quarter 2019 Levels Cash and Cash Equivalents of $40.6 Million
LENSAR Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Fourth Quarter 2020 Procedure Volumes Consistent with Fourth Quarter 2019 Levels Cash and Cash Equivalents of $40.6 Million as of December 31, 2020 ORLANDO, Fla. (March 10, 2021) -
Read more →LNSRLENSAR Expands Board of Directors with the Appointments of Aimee S. Weisner and Elizabeth G. O Farrell ORLANDO, Fla. (
LENSAR Expands Board of Directors with the Appointments of Aimee S. Weisner and Elizabeth G. ORLANDO, Fla. (February 1, 2021) LENSAR, Inc. (Nasdaq: LNSR) ( LENSAR or the Company ), a global medical technology company focused on femtosecond laser surgical solutions for the treat
Read more →LNSRDISCOVERY DRIVE ORLANDO, FL 32826 LENSAR Reports Third Quarter 2020 Financial Results and Provides Business Update Procedure Numbers Consistent with 2019 Levels Cash and Cash Equivalents of $42.7 Million as of
LENSAR Reports Third Quarter 2020 Financial Results and Provides Business Update Procedure Numbers Consistent with 2019 Levels Cash and Cash Equivalents of $42.7 Million as of September 30, 2020 ORLANDO, Fla. (November 9, 2020) LENSAR, Inc. (NASDAQ: LNSR) ( LENSAR or the Compa
Read more →LNSRThomas R. Staab, II ir.contact@lensar.com LENSAR, Inc. Begins Trading on NASDAQ ORLANDO, Fl. (
ir.contact@lensar.com LENSAR, Inc. Begins Trading on NASDAQ ORLANDO, Fl. (October 2, 2020) LENSAR, Inc. (NASDAQ: LNSR) ( LENSAR or the Company ), a global medical technology company focused on femtosecond laser surgical solutions for the treatment of cataracts, today announced
Read more →LNSRLENSAR Closes Deal With Optegra to Install Its Refractive Cataract Laser System Across All of the Specialty Eye Group's U.K. Hospitals
ORLANDO, FL--(Marketwired - Mar 20, 2014) - LENSAR, Inc., today announced it closed a deal with Optegra to install the LENSAR Laser System for refractive cataract surgery across all of its hospitals in the United Kingdom (U.K.). "Our experience in evaluating this technology over
Read more →LNSRLENSAR Initiates Clinical Study to Evaluate Lens Softening Effects of the LENSAR(TM)Laser System; Study Data May Offer Insight on Ability to Restore Lens Accommodation
ORLANDO, FL--(Marketwired - Nov 12, 2013) - LENSAR Inc., developer of the next-generation LENSAR Laser System, today announced that is has opened a clinical study under protocol to evaluate the laser system's use in softening the crystalline lens in presbyopic patients. The new "
Read more →LNSRLENSAR Secures $87 Million in Financing to Support Market Expansion of Its Laser Cataract Surgery System
ORLANDO, FL--(Marketwired - Oct 2, 2013) - LENSAR Inc., developer of the next-generation LENSAR Laser System for refractive laser-assisted cataract surgery (ReLACS), today announced the closing of $27 million in private equity financing and up to $60 million in debt financing. Ne
Read more →Competitive Position
How LNSR ranks across every disease it competes inCompetitive Position is a premium feature
See how LNSR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial